13 completed, 2 withdrawn, 1 terminated. 7 Phase 3, 5 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 5, Terminated 1, Withdrawn 1 |
| Phase 2 | 5 | Completed 4, Withdrawn 1 |
| Phase 1 | 4 | Completed 4 |
Follow sirukumab: new trials by email Literature Review of sirukumab trials Research Report on sirukumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19 Sirukumab, Placebo, Standard of Care (SOC) - Critical Confirmed Coronavirus Disease (COVID)-19 | Phase 2 | Completed | Janssen Pharmaceutica N.V., Belgium | 212 | 2020-04-24 | 2022-06-21 |
| Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica Sirukumab, Placebo to match sirukumab, Prednisone /Prednisone placebo - Polymyalgia Rheumatica | Phase 3 | Withdrawn | GlaxoSmithKline | 2018-03-15 | 2017-11-20 | |
| A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma Sirukumab, Placebo, Rescue medication - Asthma | Phase 2 | Withdrawn | GlaxoSmithKline | 2016-09-23 | 2018-08-31 | |
| Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis Sirukumab, Placebo to match sirukumab, Prednisone - Giant Cell Arteritis | Phase 3 | Terminated | GlaxoSmithKline | 161 | 2015-10-16 | 2019-07-31 |
| An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder Sirukumab 50 mg, Placebo - Depressive Disorder, Major | Phase 2 | Completed | Janssen Research & Development, LLC | 193 | 2015-07-23 | 2025-04-29 |
| A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis adalimumab 40 mg, sirukumab 100 mg, sirukumab 50 mg - Arthritis, Rheumatoid | Phase 3 | Completed | Janssen Research & Development, LLC | 559 | 2014-04-04 | 2017-10-26 |
| Bioavailability and Pharmacokinetics Study of Sirukumab in Healthy Male Participants Sirukumab (IV infusion), Sirukumab (SC injection with PFS-U), Sirukumab (SC injection with PFS-AI) - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 144 | 2014-03-01 | 2016-03-09 |
| Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003 Sirukumab 100 mg, Sirukumab 50 mg, Placebo - Arthritis, Rheumatoid | Phase 3 | Completed | Janssen Research & Development, LLC | 1820 | 2013-08-07 | 2019-05-06 |
| A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine Sirukumab 100 mg, Sirukumab 50 mg, Placebo - Arthritis, Rheumatoid | Phase 3 | Completed | Janssen Pharmaceutical K.K. | 122 | 2012-11-01 | 2016-10-27 |
| A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid Arthritis Sirukumab, Midazolam, Warfarin - Arthritis, Rheumatoid | Phase 1 | Completed | Janssen Research & Development, LLC | 12 | 2012-10-11 | 2017-03-07 |
| A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D) Placebo, Sirukumab - Arthritis, Rheumatoid | Phase 3 | Completed | Janssen Research & Development, LLC | 1670 | 2012-08-15 | 2018-01-11 |
| A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T) Placebo, Sirukumab - Arthritis, Rheumatoid | Phase 3 | Completed | Janssen Research & Development, LLC | 878 | 2012-08-06 | 2018-03-23 |
| An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis CNTO 136, Placebo - Lupus Nephritis | Phase 2 | Completed | Janssen Research & Development, LLC | 25 | 2011-08-01 | 2016-03-24 |
| A Study of the Safety and How the Body Effects a Drug CNTO 136 in Healthy Male Japanese and Caucasian Volunteers CNTO 136 - Healthy | Phase 1 | Completed | Centocor, Inc. | 62 | 2009-01-01 | 2010-04-27 |
| A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy CNTO 136 100 mg, CNTO 136 50 mg, CNTO 136 25 mg - Arthritis, Rheumatoid | Phase 2 | Completed | Centocor, Inc. | 187 | 2008-08-11 | 2018-01-23 |
| A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus 1 mg/kg CNTO 136, 4 mg/kg CNTO 136, 10 mg/kg CNTO 136 - Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic | Phase 1 | Completed | Centocor Research & Development, Inc. | 49 | 2007-03-01 | 2012-10-08 |
Arthritis, Rheumatoid (7) · Asthma (1) · COVID-19 (1) · Depressive Disorder, Major (1) · Giant Cell Arteritis (1) · Glomerulonephritis (1) · Kidney Diseases (1) · Lupus Erythematosus, Cutaneous (1) · Lupus Erythematosus, Systemic (1) · Lupus Nephritis (1) · Polymyalgia Rheumatica (1) · Proteinuria (1)
Janssen Research & Development, LLC (8) · GlaxoSmithKline (3) · Centocor, Inc. (2) · Centocor Research & Development, Inc. (1) · Janssen Pharmaceutica N.V., Belgium (1) · Janssen Pharmaceutical K.K. (1)
United States (11) · Poland (8) · Mexico (6) · Russia (6) · Germany (5) · Japan (5) · South Korea (5) · Spain (5) · Belgium (4) · Bulgaria (4) · Canada (4) · Lithuania (4) · Netherlands (4) · South Africa (4) · United Kingdom (4)
PMID 23896980, PMID 24699939, PMID 27110697, PMID 28215362, PMID 28855173, PMID 29483080, PMID 29514712, PMID 32844378, PMID 33526709, PMID 39362933
2014 (1)